The role of mecA mutations in conferring resistance to ceftobiprole and ceftaroline, cephalosporins with anti-methicillin-resistant Staphylococcus aureus (MRSA) activity, was determined with MRSA strains COL and SF8300. The SF8300 ceftaroline-passaged mutant carried a single mecA mutation, E447K (E-to-K change at position 447), and expressed low-level resistance. This mutation in COL conferred high-level resistance to ceftobiprole but only low-level resistance to ceftaroline. The COL ceftaroline-passaged mutant, which expressed high-level resistance to ceftobiprole and ceftaroline, had mutations in pbp2, pbp4, and gdpP but not mecA.
T reatment for methicillin-resistant Staphylococcus aureus (MRSA) has been complicated by increasing rates of antibiotic resistance. MRSA strains express penicillin binding protein 2a (PBP2a), encoded by mecA, which provides resistance to ␤-lactams by protecting the reactive serine in a narrow, inaccessible cleft, allowing cell wall synthesis to continue in the presence of antibiotic (1, 2) . Ceftobiprole and ceftaroline are anti-MRSA cephalosporins that inhibit PBP2a at therapeutically useful concentrations. The R2 group of ceftobiprole extends into the narrow cleft of PBP2a to access the active site, whereas ceftaroline binding causes an allosteric change in PBP2a, revealing the active site for binding by a second molecule (3, 4) . Ceftobiprole has been evaluated in clinical trials, and ceftaroline is FDA approved for treat-ment of skin and skin structure infections, including those caused by MRSA (5) (6) (7) (8) (9) (10) . Previous studies from our group have shown that passage of the COL strain in ceftobiprole selects for resistant mutants with mutations in PBP2a (11) . This study examines whether ceftaroline passage also selects for similar mutations. Passage experiments were conducted with two different MRSA backgrounds: COL, an archaic homogeneously resistant isolate from 1961, and SF8300, a heterogeneously resistant contemporary USA300 MRSA strain. COLnex and SF8300ex, mecA-negative derivative strains of COLn and SF8300, were obtained by (12) excising chromosomal staphylococcal cassette chromosome mec (SCCmec) (13) . Wild-type mecA was reintroduced on plasmid pYK20 (derived from plasmid pAW8 and containing wild-type mecA cloned from COL [14] ) into COLnex and SF8300ex for passage studies. If mecA was mediating resistance, then either curing a resistant mutant of the plasmid or introducing it into a susceptible background should result in loss or gain of phenotype, respectively, allowing determi- pAW8 containing mecA pYK20 COL B* pYK20 in COLnex passaged in ceftobiprole pYK20 COL T* pYK20 in COLnex passaged in ceftaroline pYK20 8300 T* pYK20 in SF8300ex passaged in ceftaroline a An asterisk indicates a passaged plasmid isolated during ceftobiprole (B) or ceftaroline (T) selection in a COL or SF8300 background.
nation of the contribution of mecA to resistance. Strains and plasmids used in this study are listed in Tables 1 and 2 . COLnex (pYK20) and SF8300ex(pYK20) were serially passaged in tryptic soy broth containing increasing concentrations of ceftaroline (Forest Laboratories) as previously described (11). After 28 days, COLnex(pYK20) and SF8300ex(pYK20) passaged in ceftaroline yielded two mutants, COLnex pT (pYK20 COL T*) and SF8300ex pT (pYK20 8300 T*) (an asterisk indicates a plasmid generated during ceftobiprole [B] or ceftaroline [T] selection in a COL or SF8300 background) ( Table 1) . MICs to ceftaroline, ceftobiprole, and other ␤-lactams (Sigma-Aldrich) were determined by the broth dilution method according to CLSI standards (Table 3 ) (15) . COLnex pT (pYK20 COL T*) expressed high-level resistance to both ceftaroline and ceftobiprole, with MICs of 64 g/ml and 32 g/ml, respectively. SF8300ex pT (pYK20 8300 T*) expressed low-level resistance by passage day 4, with a MIC of 4 g/ml, which remained unchanged despite 24 more passages (Table 3 and Fig. 1 ). The previously described ceftobiprole-passaged mutant of COLnex(pYK20) (11), COLnex pB (pYK20 COL B*), showed high-level resistance to both ceftobiprole and ceftaroline, with a MIC of 64 g/ml to each.
Plasmid mecA was sequenced for mutations in passaged strains. Since PBPs are the target of ␤-lactams, pbp1, -2, -3, and -4 were also sequenced. Lastly, gdpP and acrB were sequenced, as mutations in these genes had been identified in a mecA-negative ceftobiprole-resistant mutant of COL (16) . Plasmid pYK20 8300 T* (pYK20 from SF8300ex passaged in ceftaroline), had a single point mutation (G to A at coding sequence [CDS] position 1339) in mecA, resulting in a nonsynonymous amino acid change, E447K.
No mutations were present in other PBP genes, acrB, or gdpP (Table 4) .
Plasmid pYK20 COL T* (pYK20 from COLnex passaged in ceftaroline) had no mutations in mecA. A point mutation (C to T at CDS position 1327) introducing the H443Y mutation into GdpP, a point mutation (G to A at CDS position 466) introducing the D156N mutation into PBP2, and two point mutations (A to G at CDS position 601 and C to G at CDS position 723) introducing T201A and F241L mutations into PBP4 were found (Table 4) . Of note, ceftaroline passage of COL containing mecA in its natural chromosomal location also resulted in a mutant with high-level resistance but lacking mutations in mecA (data not shown). Sequence analysis of that passaged mutant revealed a point mutation in pbp2 (G to A at CDS position 1891), resulting in the amino acid change G631S, and one in pbp4 (T to A at CDS position 414), introducing a N138K mutation. These data indicate that, even in the presence of mecA, ceftaroline can select for mutations in other genes, resulting in resistance.
Curing COLnex pB (pYK20 COL B*) and SF8300ex pT (pYK20 8300 T*) of their plasmids, each of which had mecA mutations, decreased the MICs for all ␤-lactams tested (Tables 5 and 6 ). Curing COLnex pT (pYK20 COL T*) of its plasmid, which lacked mecA mutations, had no effect on MICs (Table 5) . Transforming pYK20 COL B*, which contains 6 substitution mutations in mecA, into the susceptible COLnex parent, yielding the transformant COLnex(pYK20 COL B*), resulted in high-level ceftaroline and ceftobiprole resistance. Transforming pYK20 8300 T*, which contains the single mutation E447K in mecA, into COLnex, yielding the transformant COLnex(pYK20 8300 T*), resulted in high-level resistance to ceftobiprole (MIC of 64 g/ml) but only low-level resistance to ceftaroline (MIC of 4 g/ml) ( Table 5 ). Transforming pYK20 COL B* into SF8300ex, yielding the transformant SF8300ex(pYK20 COL B*), resulted in high-level resistance to ceftaroline and ceftobiprole (MIC of 32 g/ml to each) ( Table 6) . Multiple attempts to transform SF8300ex with pYK20 8300 T* were unsuccessful.
A single amino acid change at E447 in mecA appears to play a key role in resistance. It is present in ceftobiprole-passaged COL (among other mutations) (11) , it is the only mecA mutation in the ceftaroline-passaged SF8300, and it has been reported in clinical isolates (17, 18) . Structurally, E447 resides in the penicillin-binding domain of PBP2a and interacts with the R2 group of ceftobiprole and other ␤-lactams (3, 19). E447K conferred high-level ceftobiprole resistance and low-level ceftaroline resistance in the COLnex background, likely due to structural differences between the two compounds. Multiple mutations in mecA yield high-level resistance to both antibiotics (20) . The genetic background also plays a role. Heterogeneous SF8300 passaged in ceftaroline developed low-level resistance to ceftobiprole and ceftaroline with E447K (MIC 4 g/ml). This mutation has been associated with low-level resistance to ceftaroline in clinical isolates (17) .
In conclusion, passage in either ceftaroline or ceftobiprole selects for an E447K mutation in PBP2a, a mutation found in ceftaroline-resistant clinical isolates, underscoring its importance in mediating the resistance phenotype (17, 18) . Although whole-genome sequencing was not performed, which is a limitation of this study, genes other than mecA play a role because the level of resistance differed between COL and SF8300 backgrounds upon introduction of the E447K mutation and the highly resistant passaged COL mutant had no mecA mutations. Although there are likely others, mutations in genes encoding PBP4 and GdpP seem to be particularly important, as these have been repeatedly identified in ceftobiprole-and ceftaroline-passaged mutants. The role of these genes and others is under active investigation.
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